Tiragolumab (RG6058) is another TIGIT inhibitor and is currently being used in four phase-II melanoma clinical trials in combinatorial regimens (NCT05483400, NCT05116202, NCT05060003, NCT03554083). This evidence concerns the gene TIGIT and melanoma.